Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02653599 | A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes | PHASE2 | COMPLETED | 174 | — | — | Dec 1, 2015 | Jan 1, 2017 | Feb 10, 2017 | 30 | United States |
| Arm | Type | Description |
|---|---|---|
| TTP273 300 mg daily (150 mg BID) | EXPERIMENTAL | Two 75 mg tablets of TTP273 administered orally twice daily for 12 weeks |
| TTP273 150 mg daily | EXPERIMENTAL | Two 75mg tablets of TTP273 administered orally once daily and two placebo tablets administered orally once daily for 12 weeks |
| Placebo | PLACEBO_COMPARATOR | Two matching placebo tablets administered orally twice daily for 12 weeks |
| Name | Type | Description |
|---|---|---|
| TTP273 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * The subject has a 6 month diagnosis of Type 2 diabetes mellitus prior to screening and meets the American Diabetes Association (ADA) guidelines for Type 2 diabetes mellitus. * On a stable regimen of metformin monotherapy equivalent to at least 1000 mg/day for the last 3 months...